The Sections a CRA Lives In

Part of Clinical Research Associate (CRA) Training: The Protocol as the CRA's Rulebook.

About 6 minutes. Free, in your language, no account needed.

Why this matters

Lesson 1 mapped the protocol. This lesson goes deep into the five sections that generate most of your findings: treatment and dosing, safety, concomitant medications, withdrawal, and data handling.

If you learn these five well, you will catch most of what matters at a site.

Treatment plan and investigational product

This section describes the dosing regimen — dose, frequency, route — plus titration or dose-adjustment rules, what to do about missed doses, any required pre-medication, and preparation instructions.

What you verify:

• Product was administered at the scheduled times and at the correct dose.
• Dose modifications follow the protocol's rules and are justified and documented.
• Holds and discontinuations were done per protocol.
• Required pre-medications and protocol-mandated concomitant therapies were given and recorded.
• Dispensing records, the randomization system, and the participant's source all agree.

Where it goes wrong: misread titration algorithms, errors in the randomization and supply system, similar-looking kits, and product administered before a required safety result was available.

Any departure from dosing instructions is a deviation, and dosing deviations frequently carry safety implications.

Safety assessments and adverse event reporting

This section specifies which safety assessments are required and when; how adverse events and serious adverse events are defined and graded; how severity and causality are determined; and reporting timelines and responsibilities.

What you verify:

• Required safety assessments happened on schedule.
• Safety results were reviewed by the investigator and acted on where clinically significant.
• Events recorded in source appear in the electronic data capture system, with matching detail.
• Seriousness, severity, causality and outcome are documented.
• Serious adverse events were reported within the protocol's deadline, timed from site awareness.
• Supporting documents exist: discharge summaries, laboratory results, specialist letters.

Where the deadline comes from matters. ICH E6(R3) section 2.7.2(b) requires serious adverse events to be reported to the sponsor immediately after the investigator reasonably becomes aware, with a causality assessment. It gives no number of hours. The 24-hour figure in most protocols is a protocol convention. Regional expedited clocks such as 7 or 15 days apply to the sponsor's onward reporting, not to the site.

Under-reporting is the most consequential thing you can find. Look for it actively: review hospital letters, new medications, and missed visits, not only the adverse event log.

Concomitant medications and prohibited therapies

This section lists what participants may continue or start, what is restricted or prohibited, required washout periods, and how vaccinations, over-the-counter products and herbal preparations are handled.

What you verify:

• Concomitant medication logs match the source and the medical record.
• No prohibited medication was taken, and where one was, the protocol's rules were followed.
• Washout periods were observed.
• Over-the-counter products, supplements and vaccinations are captured, because sites systematically under-record them.

Prohibited medication use can confound efficacy and create safety risk, so these deviations are rarely minor.

Withdrawal and discontinuation

This section describes when a participant must be discontinued, when they may withdraw, and what happens afterwards, including early termination visits and safety follow-up.

What you verify:

• Discontinuations meet the protocol's criteria and are justified in source.
• Early termination visits and follow-up assessments were performed and documented.
• The reason for withdrawal is accurately captured in both source and the data system.
• Participants who stopped treatment were still offered follow-up where the protocol requires it.

This last point recovers data that sites routinely lose. Stopping treatment and leaving the study are different decisions, and many participants who say they want to stop mean only the first.

Data handling, deviations and quality

This section covers how missing data are handled, source documentation and case report form requirements, how the protocol defines deviations, and the process for documenting and reporting them.

What you verify:

• The site's deviation log exists, is current, and matches what you find in the records.
• Deviations are classified as the protocol defines them, not by local habit.
• Deviations are reported through the sponsor's systems.
• Missing data are handled as the protocol specifies rather than left blank.

Where the protocol defines major and minor deviations, use its definitions in your reports. Anchoring a finding to protocol language removes most arguments.

In practice

At a VT-301 site, Leah reviews a participant whose dose was reduced at week 8.

The source note says "dose reduced due to side effects". Leah opens the protocol's titration rules. A reduction is permitted for a specific laboratory finding at a defined threshold, or for a protocol-listed adverse event.

She checks the laboratory results. The value was above the threshold, so that route does not apply. She checks the adverse event log: a moderate gastrointestinal event was recorded, which is on the protocol's list. So the reduction was permitted, but the source note does not say so.

Leah does not write "unjustified dose reduction". She writes that the dose reduction appears consistent with the protocol's rule for a listed adverse event, but that the source documentation does not record the basis for the decision, and asks the investigator to document it contemporaneously as a clarifying note.

She also finds that this is the third participant at the site with the same gap.

The decision was right. The record did not show that it was right. Those are different findings and they get different wording.

Key takeaways

• Dosing deviations frequently carry safety implications, and the CRA verifies dose, timing, titration rules, holds and discontinuations against source, dispensing records and the randomization system.
• ICH E6(R3) section 2.7.2(b) requires serious adverse events to be reported immediately after the investigator reasonably becomes aware, with a causality assessment, and states no number of hours.
• Adverse event under-reporting is found by reviewing hospital letters, new medications and missed visits, not by reading the adverse event log alone.
• Concomitant medication deviations are rarely minor, because prohibited medicines can confound efficacy and create safety risk.
• A decision that was correct but undocumented is a different finding from a decision that was wrong, and the wording of the finding must distinguish them.